Can retained gadolinium persist in tissues and contribute to oxidative, mitochondrial, neurologic, and kidney stress?

Although designed for rapid elimination, gadolinium-based contrast agents (GBCAs) can leave long-term tissue deposits, particularly in bone, skin, and brain structures, regardless of baseline renal function.

Biodistribution and retention kinetics

• Tissue accumulation: Inductively coupled plasma mass spectrometry (ICP-MS) confirms that bone and skin serve as the primary reservoirs, storing concentrations 10- to 100-fold higher than those found in the brain. Within the brain, deposition is concentrated in the dentate nucleus and globus pallidus.
• Chemical structure impact: Linear GBCAs possess lower thermodynamic stability and are highly prone to dechelation and transmetallation, resulting in significantly higher tissue retention than highly stable macrocyclic GBCAs.

Mechanistic toxicity and cellular stress

• Calcium channel blockade: Free ionic gadolinium ($Gd^{3+}$) possesses a similar ionic radius to $Ca^{2+}$, allowing it to act as a potent antagonist at voltage-gated and stretch-activated calcium channels, disrupting essential intracellular signaling.
• Mitochondrial dysfunction and ROS: This calcium dysregulation and direct mitochondrial interaction depolarizes the mitochondrial membrane, impairs ATP synthesis, opens the mitochondrial permeability transition pore (mPTP), and elevates reactive oxygen species (ROS), culminating in caspase-3-mediated apoptosis.
• Organ-specific stress: In renal tissue, retained gadolinium induces proximal tubular damage, lipid vesicle accumulation, and oxidative stress. While preclinical models confirm that $Gd^{3+}$ causes direct neurotoxicity, clinical studies in humans with normal renal function have not yet established a reproducible, causal link between brain deposition and clinical neurological symptoms.

Bottom line

• Retained gadolinium—particularly from less stable linear agents—persistently deposits in bones, skin, and brain structures regardless of renal clearance. Preclinical evidence confirms this retention drives oxidative stress, mitochondrial failure, and calcium dysregulation, although clear clinical neurological manifestation in patients with normal kidney function remains unproven.